R & D
Our product pipeline includes drug candidates for the treatment of mitochondrial and other diseases.
R007 Overview: A Novel Approach
R007 Mechanism of Action
Instead of attempting to treat the multiple genetic causes of mitochondrial dysfunction, we aim to treat the consequences of mitochondrial dysfunction, regardless of the cause. We are testing the drug candidate R007.
The preclinical studies indicate that R007 acts in the cytosol outside the mitochondrion, resulting in reversal of the dysregulation of central nodes of the nutrient-sensing signaling network, in particular AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), and mammalian target of rapamycin complex 1 (mTORC1).
tRNA Drug Discovery Program
In addition to our R007 product candidate, we have developed a proprietary drug discovery platform for new precision medicines that target a novel family of pharmaceutical targets: defective transfer RNAs.
Potential Drug Targets on Transfer RNA
Transfer RNA is the most abundant ribonucleic acid in the human cell, and delivers amino acids to biological factories called ribosomes, to make the proteins that drive all cellular operations. Defects in transfer RNAs are associated with several human diseases.
tRNA Modification Map
RiboNova is applying its technology to map RNA modifications in a wide range of human diseases, to identify clinically useful biomarkers and powerful therapeutic targets for drug development.
Disruptive Technology for Pharmaceutical Innovation